Sio Gene Therapies (NASDAQ:SIOX – Get Rating) was downgraded by Cantor Fitzgerald from an “overweight” rating to a “neutral” rating in a research report issued on Thursday, The Fly reports. They presently have a $0.80 target price on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 153.16% from the stock’s previous close.
Several other analysts have also recently weighed in on SIOX. SVB Leerink cut Sio Gene Therapies from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $6.00 to $1.00 in a report on Tuesday, February 1st. HC Wainwright dropped their price target on Sio Gene Therapies from $10.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, February 1st. Finally, Zacks Investment Research raised Sio Gene Therapies from a “sell” rating to a “hold” rating in a report on Thursday, April 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Sio Gene Therapies has a consensus rating of “Hold” and a consensus target price of $4.43.
Shares of SIOX traded down $0.29 during mid-day trading on Thursday, reaching $0.32. The company’s stock had a trading volume of 123,667 shares, compared to its average volume of 454,850. Sio Gene Therapies has a 1-year low of $0.54 and a 1-year high of $2.95. The stock has a market cap of $23.05 million and a P/E ratio of -0.44. The business has a 50-day simple moving average of $0.64 and a two-hundred day simple moving average of $1.17.
Several institutional investors and hedge funds have recently modified their holdings of the company. Two Sigma Securities LLC bought a new position in shares of Sio Gene Therapies in the 3rd quarter valued at $28,000. BlackRock Inc. boosted its holdings in shares of Sio Gene Therapies by 20.9% during the 3rd quarter. BlackRock Inc. now owns 142,292 shares of the company’s stock valued at $309,000 after acquiring an additional 24,583 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Sio Gene Therapies by 9.5% during the 4th quarter. Geode Capital Management LLC now owns 431,208 shares of the company’s stock valued at $556,000 after acquiring an additional 37,404 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Sio Gene Therapies by 136.5% during the 3rd quarter. Morgan Stanley now owns 68,383 shares of the company’s stock valued at $149,000 after acquiring an additional 39,471 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Sio Gene Therapies by 42.9% during the 4th quarter. State Street Corp now owns 157,200 shares of the company’s stock valued at $203,000 after acquiring an additional 47,200 shares in the last quarter.
About Sio Gene Therapies (Get Rating)
Sio Gene Therapies, Inc, a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis.
- Get a free copy of the StockNews.com research report on Sio Gene Therapies (SIOX)
- There’s An Institutional Floor In Keurig Dr. Pepper
- Ford Falls Despite Optimistic Outlook
- Harley-Davidson Skids Into A Buying Opportunity
- Facebook (NASDAQ: FB) Soars And Wall Street Delights
- Automatic Data Processing Is Ready To Scale New Heights
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.